Post Reply
141-160 of 4174
How will the afternoon movement be like?
I am still holding to my 1/2 holdings to fight.
offloaded all at 0.235 seeing not much uptick at the moment. Made few K gain
Sold 0.255
Sgvale ( Date: 22-Sep-2021 09:10) Posted:
|
Sold all bought at 0.198
Sgvale ( Date: 21-Sep-2021 15:12) Posted:
|
Still going strong!
SIA and travel related companies likely to benefit much from NAB Test ...
What are the Importance and Benefits of Neutralizing Antibodies in COVID testing?
1. Neutralizing Antibodies (or Late arriving IgG) are key to reducing infection.
2. NAb prevents the virus from fastening to the host cell.
3. The prevalence of these antibodies (in High Titre) determine:
a) If the individual has an excellent humoral immunity
b) If they can donate convalescent plasma (no longer recommended in India as a viable fight against Covid-19)
c) If the vaccination is effective, and thus the level of precautions that are needed
4. NAb(s) provide zero cross-reactivity with any other coronavirus infections.
5. The testing of NAb(s) can help the patients to segregate between mild, moderate, and severe categories.
6. They assist in the tracking of infection chains.
7. Answer epidemiological, virological, and clinic questions, including, but not limited to, whether a robust antibody response has occurred.
8. The short-term to long-term immunity and the treatment regime can be devised explicitly for an individual by testing NAb(s).
9. Neutralizing antibodies are more applicable to be catered as the advanced Diagnostic and therapeutic marker to address the resurgence of COVID infections in the country and how many positive individuals have remained asymptomatic.
10. The presence of NAb highlights immunity against viral infections.
What are the Importance and Benefits of Neutralizing Antibodies in COVID testing?
1. Neutralizing Antibodies (or Late arriving IgG) are key to reducing infection.
2. NAb prevents the virus from fastening to the host cell.
3. The prevalence of these antibodies (in High Titre) determine:
a) If the individual has an excellent humoral immunity
b) If they can donate convalescent plasma (no longer recommended in India as a viable fight against Covid-19)
c) If the vaccination is effective, and thus the level of precautions that are needed
4. NAb(s) provide zero cross-reactivity with any other coronavirus infections.
5. The testing of NAb(s) can help the patients to segregate between mild, moderate, and severe categories.
6. They assist in the tracking of infection chains.
7. Answer epidemiological, virological, and clinic questions, including, but not limited to, whether a robust antibody response has occurred.
8. The short-term to long-term immunity and the treatment regime can be devised explicitly for an individual by testing NAb(s).
9. Neutralizing antibodies are more applicable to be catered as the advanced Diagnostic and therapeutic marker to address the resurgence of COVID infections in the country and how many positive individuals have remained asymptomatic.
10. The presence of NAb highlights immunity against viral infections.
More room for upside then??
This article out when share prices still around 40+ ... compare with now ....
WBdisciple ( Date: 21-Sep-2021 21:46) Posted:
|
This is an article based on the previous announcement related to their NAB test kit..
BIOLIDICS on July 9 entered into a five-year licence agreement with Accelerate Technologies, the commercialisation arm of the Agency for Science, Technology and Research (A*Star), to use the agency' s technology for the detection of Covid-19 viral spike/Angiotensin Converting Enzyme 2 (ACE2) blocking antibodies.
The Catalist-listed company said in a bourse filing late on Tuesday that it aims to develop new serology tests which incorporate the technology.
Under the agreement, Accelerate Technologies has granted Biolidics non-exclusive worldwide rights to use the technology for diagnostic use for the five-year term to further develop the technology, and the right to market serology tests which incorporate the technology.
ACE2 is a cellular receptor for coronaviruses such as Sars and the novel coronavirus. Spike proteins from these coronaviruses recognise and bind to ACE2 on the surface of target cells, allowing the virus to enter these cells and infect the person.
Most commercially available serology tests against Covid-19, including Biolidics' own Covid-19 antibody test kit launched on March 30, detects IgG and IgM antibodies, which are a group of antibodies produced by the body in response to a novel coronavirus infection.
As such, these serology tests are currently used only as an assistive tool in the detection of Covid-19, and are not able to detect specific antibodies which bind to the novel coronavirus and interfere with its ability to infect target cells, Biolidics said
It added that serology tests incorporating A*Star' s technology allow for the detection of such Covid-19 viral spike/ACE2 blocking antibodies that may interfere with the ability of the virus to infect target cells, and could provide an indication of protective immunity against Covid-19.
Biolidics added that there is currently little information on the level of antibodies sufficient to confer protective immunity to an individual, and how long such protective immunity against Covid-19 may last in an individual.
It also cautioned shareholders and potential investors that policies in relation to the diagnosis and/or detection of the Covid-19 virus and/or antibodies in various jurisdictions could change in response to developments in the Covid-19 situation, which was " evolving rapidly" .
" There is no certainty that the group will be able to successfully commercialise the serology tests which incorporate the technology, if developed," it added.
It said the agreement is not expected to have a material impact on its earnings per share and the net asset value of the group for the current financial year ending Dec 31, 2020.
Biolidics signs five-year licence with A*Star arm eyes development of new Covid-19 test kits
WED, JUL 15, 2020 - 8:42 AM
UPDATED WED, JUL 15, 2020 - 5:22 PM
BIOLIDICS on July 9 entered into a five-year licence agreement with Accelerate Technologies, the commercialisation arm of the Agency for Science, Technology and Research (A*Star), to use the agency' s technology for the detection of Covid-19 viral spike/Angiotensin Converting Enzyme 2 (ACE2) blocking antibodies.
The Catalist-listed company said in a bourse filing late on Tuesday that it aims to develop new serology tests which incorporate the technology.
Under the agreement, Accelerate Technologies has granted Biolidics non-exclusive worldwide rights to use the technology for diagnostic use for the five-year term to further develop the technology, and the right to market serology tests which incorporate the technology.
ACE2 is a cellular receptor for coronaviruses such as Sars and the novel coronavirus. Spike proteins from these coronaviruses recognise and bind to ACE2 on the surface of target cells, allowing the virus to enter these cells and infect the person.
Most commercially available serology tests against Covid-19, including Biolidics' own Covid-19 antibody test kit launched on March 30, detects IgG and IgM antibodies, which are a group of antibodies produced by the body in response to a novel coronavirus infection.
As such, these serology tests are currently used only as an assistive tool in the detection of Covid-19, and are not able to detect specific antibodies which bind to the novel coronavirus and interfere with its ability to infect target cells, Biolidics said
It added that serology tests incorporating A*Star' s technology allow for the detection of such Covid-19 viral spike/ACE2 blocking antibodies that may interfere with the ability of the virus to infect target cells, and could provide an indication of protective immunity against Covid-19.
Biolidics added that there is currently little information on the level of antibodies sufficient to confer protective immunity to an individual, and how long such protective immunity against Covid-19 may last in an individual.
It also cautioned shareholders and potential investors that policies in relation to the diagnosis and/or detection of the Covid-19 virus and/or antibodies in various jurisdictions could change in response to developments in the Covid-19 situation, which was " evolving rapidly" .
" There is no certainty that the group will be able to successfully commercialise the serology tests which incorporate the technology, if developed," it added.
It said the agreement is not expected to have a material impact on its earnings per share and the net asset value of the group for the current financial year ending Dec 31, 2020.
I think BB will switched play to hatten land. Strong surge from hatten land last 1 hr.
Sgvale ( Date: 21-Sep-2021 18:21) Posted:
|
THis NAB test kit is owned by Biolidics with A*STAR technology...different from the current ones in their test kit portfolio (which is OEM or on a distribution basis).
Covid-19 Neutralizing Antibody Test critical for India&rsquo s fight against Coronavirus
August 26, 2021 2:14 PM
Neutralizing antibody (NAb) is the antibody that defends cells from pathogens, which are organisms that cause disease (in this case, SARS-CoV-2).
Covid-19, Neutralizing Antibody Test, Coronavirus, Pfizer, Moderna, Covid-19 vaccine, Covishield, SARS-CoV-2 virus, NAb, DCGI
WHO supports studies based on neutralizing antibody tests as they are critical for understanding infection' s extent and risk factors.
By Jatin Mahajan,
US Centre for Disease Control has recommended a 3rd dose of the Pfizer and Moderna Covid-19 vaccine for developing adequate antibodies amongst immunocompromised people. Some experts recommend a 3rd dose of Covishield six months after the second dose for depleting antibodies. The UK has recently announced 3rd vaccination dose for those above 50 years to eradicate the threat from the infection.
These developments are a direct fallout of the innumerable cases of low antibodies level even after two doses of the vaccines. These immunocompromised people may be active cancer treatment receivers, organ transplant patients, or those undertaking immunosuppressant medicines. They may be those who have received stem cell transplants in the past two years. HIV patients and those undergoing active treatment with high-dose corticosteroids and similar drugs that suppress the immune response also fall in this category. They also comprise others with moderate or severe primary immunodeficiency.
So how can we be sure if our antibody levels are adequately high against Covid-19? The solution is simple and available. The Covid-19 Neutralizing Antibody Microlisa test is critical and crucial to India&rsquo s fight against the corona pandemic because it showcases how effective the vaccination has been for creating neutralizing antibodies against the SARS-CoV-2 virus.
Virus neutralization is the gold standard for finding antibody efficacy. Covid-19 neutralizing antibody test detects neutralizing antibodies against SARS-CoV-2. Neutralization assays are complex biological lab tests, the only method to functionally test antibodies for their ability to prevent cell infection by SARS-CoV-2. Many countries are now pushing for SARS-CoV-2 antibodies at the population level and taking necessary corrective actions.
WHO supports studies based on neutralizing antibody tests as they are critical for understanding infection&rsquo s extent and risk factors. Some countries that have implemented SARS-CoV-2 antibodies testing to monitor the development of herd immunity include the USA, UK, Australia, China, Thailand, Germany, Sweden, Austria, Switzerland, Finland, Brazil, Iceland, Spain, amongst others.
What is Neutralizing Antibody?
Neutralizing antibody (NAb) is the antibody that defends cells from pathogens, which are organisms that cause disease (in this case, SARS-CoV-2). The body produces them naturally as part of its immune response, and both infections and vaccinations against diseases trigger their production.
NAb stops infections by incapacitating the invading pathogen by Blocking cell entry, replication, or other vital function. Neutralizing antibodies can result in lifelong immunity to certain infections. Therefore, they are practical to see if a person has developed immunity to disease after they have recovered from it or post-vaccination.
What are the Importance and Benefits of Neutralizing Antibodies in COVID testing?
1. Neutralizing Antibodies (or Late arriving IgG) are key to reducing infection.
2. NAb prevents the virus from fastening to the host cell.
3. The prevalence of these antibodies (in High Titre) determine:
a) If the individual has an excellent humoral immunity
b) If they can donate convalescent plasma (no longer recommended in India as a viable fight against Covid-19)
c) If the vaccination is effective, and thus the level of precautions that are needed
4. NAb(s) provide zero cross-reactivity with any other coronavirus infections.
5. The testing of NAb(s) can help the patients to segregate between mild, moderate, and severe categories.
6. They assist in the tracking of infection chains.
7. Answer epidemiological, virological, and clinic questions, including, but not limited to, whether a robust antibody response has occurred.
8. The short-term to long-term immunity and the treatment regime can be devised explicitly for an individual by testing NAb(s).
9. Neutralizing antibodies are more applicable to be catered as the advanced Diagnostic and therapeutic marker to address the resurgence of COVID infections in the country and how many positive individuals have remained asymptomatic.
10. The presence of NAb highlights immunity against viral infections.
Covid-19 Neutralizing Antibody Test critical for India&rsquo s fight against Coronavirus
August 26, 2021 2:14 PM
Neutralizing antibody (NAb) is the antibody that defends cells from pathogens, which are organisms that cause disease (in this case, SARS-CoV-2).
Covid-19, Neutralizing Antibody Test, Coronavirus, Pfizer, Moderna, Covid-19 vaccine, Covishield, SARS-CoV-2 virus, NAb, DCGI
WHO supports studies based on neutralizing antibody tests as they are critical for understanding infection' s extent and risk factors.
By Jatin Mahajan,
US Centre for Disease Control has recommended a 3rd dose of the Pfizer and Moderna Covid-19 vaccine for developing adequate antibodies amongst immunocompromised people. Some experts recommend a 3rd dose of Covishield six months after the second dose for depleting antibodies. The UK has recently announced 3rd vaccination dose for those above 50 years to eradicate the threat from the infection.
These developments are a direct fallout of the innumerable cases of low antibodies level even after two doses of the vaccines. These immunocompromised people may be active cancer treatment receivers, organ transplant patients, or those undertaking immunosuppressant medicines. They may be those who have received stem cell transplants in the past two years. HIV patients and those undergoing active treatment with high-dose corticosteroids and similar drugs that suppress the immune response also fall in this category. They also comprise others with moderate or severe primary immunodeficiency.
So how can we be sure if our antibody levels are adequately high against Covid-19? The solution is simple and available. The Covid-19 Neutralizing Antibody Microlisa test is critical and crucial to India&rsquo s fight against the corona pandemic because it showcases how effective the vaccination has been for creating neutralizing antibodies against the SARS-CoV-2 virus.
Virus neutralization is the gold standard for finding antibody efficacy. Covid-19 neutralizing antibody test detects neutralizing antibodies against SARS-CoV-2. Neutralization assays are complex biological lab tests, the only method to functionally test antibodies for their ability to prevent cell infection by SARS-CoV-2. Many countries are now pushing for SARS-CoV-2 antibodies at the population level and taking necessary corrective actions.
WHO supports studies based on neutralizing antibody tests as they are critical for understanding infection&rsquo s extent and risk factors. Some countries that have implemented SARS-CoV-2 antibodies testing to monitor the development of herd immunity include the USA, UK, Australia, China, Thailand, Germany, Sweden, Austria, Switzerland, Finland, Brazil, Iceland, Spain, amongst others.
What is Neutralizing Antibody?
Neutralizing antibody (NAb) is the antibody that defends cells from pathogens, which are organisms that cause disease (in this case, SARS-CoV-2). The body produces them naturally as part of its immune response, and both infections and vaccinations against diseases trigger their production.
NAb stops infections by incapacitating the invading pathogen by Blocking cell entry, replication, or other vital function. Neutralizing antibodies can result in lifelong immunity to certain infections. Therefore, they are practical to see if a person has developed immunity to disease after they have recovered from it or post-vaccination.
What are the Importance and Benefits of Neutralizing Antibodies in COVID testing?
1. Neutralizing Antibodies (or Late arriving IgG) are key to reducing infection.
2. NAb prevents the virus from fastening to the host cell.
3. The prevalence of these antibodies (in High Titre) determine:
a) If the individual has an excellent humoral immunity
b) If they can donate convalescent plasma (no longer recommended in India as a viable fight against Covid-19)
c) If the vaccination is effective, and thus the level of precautions that are needed
4. NAb(s) provide zero cross-reactivity with any other coronavirus infections.
5. The testing of NAb(s) can help the patients to segregate between mild, moderate, and severe categories.
6. They assist in the tracking of infection chains.
7. Answer epidemiological, virological, and clinic questions, including, but not limited to, whether a robust antibody response has occurred.
8. The short-term to long-term immunity and the treatment regime can be devised explicitly for an individual by testing NAb(s).
9. Neutralizing antibodies are more applicable to be catered as the advanced Diagnostic and therapeutic marker to address the resurgence of COVID infections in the country and how many positive individuals have remained asymptomatic.
10. The presence of NAb highlights immunity against viral infections.
Like in the past, Biolidics rise will not continue the next day.
Oops sorry I meant 1 cent I buy earlier typo error
2cents I buy
If drop to 0.20, I buy.
wasted i nvr notice this..
Bryant24 ( Date: 21-Sep-2021 16:22) Posted:
|
Took some profit at 24.
Kio most of my TG losses.
Kio most of my TG losses.
Yet another new fairy tale that soon reveal as yet another horrific nightmare !!!!! 
25 many buyer stuck there
Stocksguru ( Date: 21-Sep-2021 15:49) Posted:
|